Peer-reviewed veterinary case report
How dose intensity affects outcomes in dogs with T-cell lymphoma
By Lenz, Jennifer A et al.·Published in Veterinary and comparative oncology·2023·Department of Clinical Science & Advanced Medicine, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Calculation of dose intensity and comparison of published methods using a cohort of canine T-cell lymphoma patients undergoing CHOP-based chemotherapy.
- Species:
- dog
Plain-English summary
A group of 40 dogs with T-cell lymphoma underwent a chemotherapy treatment called CHOP, which is commonly used for this type of cancer. Despite receiving varying doses of the treatment, the study found that the amount of chemotherapy they actually received did not significantly affect how long they lived or how well the treatment worked. On average, these dogs lived about 196 days after starting treatment, but outcomes were generally poor regardless of the dose intensity. This suggests that improvements in treatment protocols are needed for better results in dogs with T-cell lymphoma.
People also search for: dog T-cell lymphoma treatment · CHOP chemotherapy for dogs · dog cancer survival rates
Abstract
Methods of calculating and reporting dose intensity (DI) of CHOP-based protocols in the veterinary literature vary. The goal of this retrospective study is to examine the prognostic significance of the average percentage of planned DI received in a cohort of canine T-cell lymphoma patients treated with a modified CHOP protocol with corresponding toxicity and efficacy data. Our data set of 40 dogs was analysed using various previously published methods for calculating DI. Median progression-free survival and overall survival were 91 and 196 days, respectively. Receiving a higher percentage of planned DI was not found to be associated with patient outcome. Outcomes remain poor for dogs with T-cell lymphoma treated with CHOP-based chemotherapy irrespective of received DI. Standard methods of DI calculation and reporting should be adopted in veterinary oncology to enable repeatable and rigorous comparisons of published chemotherapy protocols and to ascertain the potential prognostic relevance of DI in canine lymphoma patients.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/36929679/